ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,587.00
0.23%
S&P ASX All Technology
2,972.40
0.12%
Brent Oil
83.89
0.42%
US Dollar vs AUD
1.52742
-0.23%
Bitcoin
57,594.03
-1.11%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. OKYO Pharma Ltd (OKYO)

  7. OKYO Pharma Ltd (OKYO) News

OKYO OKYO Pharma Ltd

1.50
0.00 (0.00%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
OKYO Pharma Ltd OKYO NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.00 0.00% 1.50 10:00:00
Open Price Low Price High Price Close Price Previous Close
1.50 1.485 1.50 1.50 1.50
more quote information »

Recent News

Date Time Source Heading
30/4/202421:00GLOBEOKYO Pharma Announces Upcoming Presentation of OK-101 Phase..
09/4/202409:00GLOBEOKYO Pharma to Reschedule Key Opinion Leader Event in Dry..
02/4/202422:00GLOBEOKYO Pharma Announces Upcoming Presentation of OK-101 Phase..
22/3/202422:00GLOBEOKYO Pharma Announces OK-101 Successfully Achieved..
21/3/202422:00GLOBEOKYO Pharma to Host Key Opinion Leader Event to Discuss New..
20/3/202422:00GLOBEOKYO Pharma to Release New and Comprehensive Data from Phase..
09/2/202423:36IHNWOKYO Pharma Receives FDA Approval of IND for OK-101 in..
09/2/202423:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/2/202423:00GLOBEOKYO Pharma Receives FDA Approval of IND for OK-101 in..
31/1/202423:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/1/202423:00GLOBEOKYO Pharma Announces Distinguished Ophthalmologists with..
08/1/202423:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202423:00GLOBEOKYO Pharma Announces OK-101 Successfully Achieved..
06/1/202401:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/1/202401:30GLOBEOKYO Pharma to Present at the Biotech Showcase Conference in..
21/12/202323:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202309:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/12/202308:56EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202323:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202323:00GLOBEOKYO Pharma Announces Last Patient Enrolled in OK-101 Phase..
29/11/202323:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/11/202307:55EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202307:59EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
31/10/202322:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202322:00GLOBEOKYO Pharma Announces $5.84 Million Cash Raise and Payables..
10/10/202322:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/10/202302:34IHNWOKYO Pharma Announces Filing of an Investigational New Drug..
09/10/202322:00GLOBEOKYO Pharma Announces Filing of an Investigational New Drug..
05/10/202322:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/10/202322:00GLOBEOKYO Pharma Announces Positive Safety Data Profile for the..
16/9/202306:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/9/202321:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/9/202321:00GLOBEOKYO Pharma Announces Closing of $4.0 Million Registered..
15/9/202320:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15/9/202300:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/9/202300:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/9/202323:15GLOBEOKYO Pharma Announces Pricing of $4.0 Million Registered..
14/9/202322:45GLOBEOKYO Pharma Limited Announces Withdrawal of Public Offering
14/9/202306:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/9/202306:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/9/202306:05GLOBEOKYO Pharma Announces Public Offering of Ordinary Shares
08/9/202321:04IHNWOKYO Pharma Completes Enrollment in Phase 2 Clinical Trial..
08/9/202321:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/9/202321:00GLOBEOKYO Pharma Completes Enrollment in Phase 2 Clinical Trial..
30/8/202321:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/8/202321:00GLOBEOKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2..
29/8/202321:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/8/202321:00GLOBEOKYO Pharma Limited Regains Compliance with Nasdaq Listing..
26/8/202301:33EDGAR2Form 20-F/A - Annual and transition report of foreign..
15/8/202323:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..

Your Recent History

NASDAQ
OKYO
OKYO Pharma
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved